Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
solid tumor
Biotech
Chinese biotech helmed by AZ veteran reels in $108M series B
D3 Bio will use the funds to advance its lead KRAS inhibitor into phase 3 studies.
James Waldron
Dec 10, 2025 3:45am
Crescent inks $80M Kelun deal, adding ADC to mix with bispecific
Dec 4, 2025 9:50am
GSK pens $50M pact to join Big Pharma peers in emerging modality
Nov 19, 2025 4:40am
Genmab sheds another clinical ADC from $1.8B ProfoundBio buy
Nov 17, 2025 2:17pm
Bayer bails on Vividion tumor drug in early-stage clear-out
Nov 12, 2025 8:10am
Cullinan puts kibosh on 2 cancer assets amid autoimmune refocus
Nov 6, 2025 1:26pm
